Keros Therapeutics (KROS) Retained Earnings (2019 - 2025)
Keros Therapeutics (KROS) posted Retained Earnings of $1.2 billion for Q4 2025, up 355.17% on a QoQ basis from -$458.3 million in Q3 2025, and up 305.61% year-over-year from $288.3 million in Q4 2024.
Keros Therapeutics (KROS) Retained Earnings (2019 - 2025) Analysis & Trends
Keros Therapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at $1.2 billion for Q4 2025.
- Quarterly Retained Earnings rose 305.61% year-over-year to $1.2 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 billion (up 305.61% YoY) and the FY2025 annual result came in at $1.2 billion, up 305.61% from the prior year.
- Retained Earnings was $1.2 billion for Q4 2025 at Keros Therapeutics, up from -$458.3 million in the prior quarter.
- Across five years, Retained Earnings topped out at $1.2 billion in Q4 2025 and bottomed at -$568.8 million in Q4 2024.
- A 5-year average of $289.9 million and a median of $369.2 million in 2021 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2021 — Retained Earnings jumped 1143.9% — and 2023, when it sank 177.59%.
- Keros Therapeutics' Retained Earnings stood at $366.9 million in 2021, then surged by 37.86% to $505.9 million in 2022, then plunged by 175.4% to -$381.4 million in 2023, then plunged by 49.12% to -$568.8 million in 2024, then jumped by 305.61% to $1.2 billion in 2025.
- Business Quant data shows KROS's Retained Earnings at $1.2 billion in Q4 2025, -$458.3 million in Q3 2025, and $1.2 billion in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Keros Therapeutics | 377.42 Mn | 90.02 Mn | - | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.17 Bn |
| Sep 30, 2025 | -458.30 Mn |
| Jun 30, 2025 | 1.16 Bn |
| Mar 31, 2025 | 1.15 Bn |
| Dec 31, 2024 | -568.78 Mn |
| Sep 30, 2024 | 1.06 Bn |
| Jun 30, 2024 | 890.71 Mn |
| Mar 31, 2024 | -424.54 Mn |
| Dec 31, 2023 | -381.43 Mn |
| Sep 30, 2023 | -341.18 Mn |
| Jun 30, 2023 | 628.00 Mn |
| Mar 31, 2023 | -264.24 Mn |
| Dec 31, 2022 | 505.86 Mn |
| Sep 30, 2022 | 439.74 Mn |
| Jun 30, 2022 | 386.41 Mn |
| Mar 31, 2022 | 371.43 Mn |
| Dec 31, 2021 | 366.93 Mn |
| Sep 30, 2021 | -116.82 Mn |
| Jun 30, 2021 | -96.52 Mn |
| Mar 31, 2021 | 329.27 Mn |